CRCNA, INSERM, Université de Nantes, Nantes , France ; GIP ARRONAX , Saint-Herblain , France ; Service de Médecine Nucléaire - CHU de Nantes , Nantes , France.
Published: September 2015
AI Article Synopsis
Article Abstract
Mapping tumor hypoxia is a great challenge in positron emission tomography (PET) imaging as the precise functional information of the biological processes is needed for many effective therapeutic strategies. Tumor hypoxia has been widely reported as a poor prognostic indicator and is often associated with tumor aggressiveness, chemo- and radio-resistance. An accurate diagnosis of hypoxia is a challenge and is crucial for providing accurate treatment for patients' survival benefits. This challenge has led to the emergence of new and novel PET tracers for the functional and metabolic characterization of tumor hypoxia non-invasively. Among these tracers, copper semicarbazone compound [64Cu]-diacetyl-bis(N (4)-methylthiosemicarbazone) (=64Cu-ATSM) has been developed as a tracer for hypoxia imaging. This review focuses on 64Cu-ATSM PET imaging and the concept is presented in two sections. The first section describes its in vitro development and pre-clinical testing and particularly its affinity in different cell lines. The second section describes the controversial reports on its specificity for hypoxia imaging. The review concludes that 64Cu-ATSM - more than a hypoxic tracer, exhibits tracer accumulation in tumor, which is linked to the redox potential and reactive oxygen species. The authors concluded that 64Cu-ATSNM is a marker of over-reduced cell state and thus an indirect marker for hypoxia imaging. The affinity of 64Cu-ATSM for over-reduced cells was observed to be a complex phenomenon. And to provide a definitive and convincing mechanism, more in vivo studies are needed to prove the diagnostic utility of 64Cu-ATSM.
Background/aims: Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that severely affects cognitive functions and memory. Early detection is crucial for timely intervention and improved patient outcomes. However, traditional diagnostic tools, such as MRI and PET scans, are costly and less accessible.
Undifferentiated pleomorphic sarcoma, an exceedingly rare and aggressive primary cardiac tumor arising from mesenchymal stem cells, is associated with poor prognosis and high mortality despite adequate treatment. A 52-year-old female presented with a 2-month history of angina and dyspnea on exertion. Her clinical history included severe acute respiratory syndrome coronavirus 2 myocarditis and iron deficiency anemia.
The thyroid is a rare site for finding tumor metastases. Renal, colorectal, pulmonary, and mammary origin are the most frequent primary neoplasms. Clinical suspicion, early diagnosis, and active surveillance are important during follow-up.
Background: Accurate diagnosis and understanding of brain disorders are crucial for the best treatment. While multimodal neuroimaging is essential, it has its limitations. Conventional computed tomography (CT) and magnetic resonance imaging (MRI) provide detailed anatomical information but lack molecular insights, while 18F-fluorodeoxyglucose-positron emission tomography (FDG PET) offers metabolic data but often has limited spatial resolution.
